BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Feola T, Puliani G, Sesti F, Modica R, Centello R, Minotta R, Cannavale G, Di Meglio S, Di Vito V, Lauretta R, Appetecchia M, Colao A, Lenzi A, Isidori AM, Faggiano A, Giannetta E. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study. J Endocrinol Invest 2022. [PMID: 35040099 DOI: 10.1007/s40618-021-01715-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 White BE, Russell B, Remmers S, Rous B, Chandrakumaran K, Wong KF, Van Hemelrijck M, Srirajaskanthan R, Ramage JK. Sex Differences in Survival from Neuroendocrine Neoplasia in England 2012–2018: A Retrospective, Population-Based Study. Cancers 2023;15:1863. [DOI: 10.3390/cancers15061863] [Reference Citation Analysis]
2 Ma J, Hu X, Li L, Rao Z, Zhang C. Efficacy and safety of (177)Lu-DOTATATE targeted therapy in advanced/metastatic pulmonary neuroendocrine tumors: A systematic review and meta-analysis. Front Oncol 2022;12:993182. [PMID: 36505778 DOI: 10.3389/fonc.2022.993182] [Reference Citation Analysis]
3 Lan X, Fazio N, Abdel-rahman O. Exploring the Relationship between Obesity, Metabolic Syndrome and Neuroendocrine Neoplasms. Metabolites 2022;12:1150. [DOI: 10.3390/metabo12111150] [Reference Citation Analysis]
4 Abe K, Kitago M, Iwasaki E, Yagi H, Abe Y, Hasegawa Y, Hori S, Tanaka M, Nakano Y, Kitagawa Y. Reconsideration of operative indications in pancreatic neuroendocrine neoplasms. World J Surg Onc 2022;20:366. [DOI: 10.1186/s12957-022-02834-5] [Reference Citation Analysis]
5 Lu Z, Li T, Liu C, Zheng Y, Song J. Development and validation of a survival prediction model and risk stratification for pancreatic neuroendocrine neoplasms. J Endocrinol Invest 2022. [DOI: 10.1007/s40618-022-01956-7] [Reference Citation Analysis]
6 Tong H, Wang M, Liu J, Guo C, Wang Z, Wang J, Chen X. Bone Loss in Patients with Pancreatic Neuroendocrine Tumors. J Clin Med 2022;11. [PMID: 36431178 DOI: 10.3390/jcm11226701] [Reference Citation Analysis]
7 Liang W, Xu X, Liu Y, Cui J, Gao Y, Wang C, Zhuang Z, Zhang K, Xi H, Cai A, Wei B, Chen L. Defining the impact of platelet-to-lymphocyte ratio on patient survival with gastric neuroendocrine neoplasm: a retrospective cohort analysis. World J Surg Onc 2022;20:356. [DOI: 10.1186/s12957-022-02822-9] [Reference Citation Analysis]
8 Modica R, La Salvia A, Liccardi A, Cannavale G, Minotta R, Benevento E, Faggiano A, Colao A. Lipid Metabolism and Homeostasis in Patients with Neuroendocrine Neoplasms: From Risk Factor to Potential Therapeutic Target. Metabolites 2022;12:1057. [DOI: 10.3390/metabo12111057] [Reference Citation Analysis]
9 Caldeira TCM, Soares MM, de Sousa TM, Veiga IPA, da Silva LES, Claro RM. The Prevalence of Risk and Protective Factors for Noncommunicable Diseases (NCDs) among Brazilian Adults with Pre-Obesity and Obesity. Obesities 2022;2:317-325. [DOI: 10.3390/obesities2030026] [Reference Citation Analysis]
10 Jiang S, Yang F, Zhang L, Sang X, Lu X, Zheng Y, Xu Y. A prognostic nomogram based on log odds of positive lymph nodes to predict the overall survival in biliary neuroendocrine neoplasms (NENs) patients after surgery. J Endocrinol Invest 2022. [PMID: 35908009 DOI: 10.1007/s40618-022-01874-8] [Reference Citation Analysis]
11 Modica R, Liccardi A, Minotta R, Cannavale G, Benevento E, Colao A. Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives. Expert Rev Endocrinol Metab 2022;:1-15. [PMID: 35822906 DOI: 10.1080/17446651.2022.2099840] [Reference Citation Analysis]
12 Zhang P, Xiao Z, Xu H, Zhu X, Wang L, Huang D, Liang Y, Ni Q, Chen J, Yu X, Luo G. Hyperglycemia is associated with adverse prognosis in patients with pancreatic neuroendocrine neoplasms. Endocrine 2022. [PMID: 35790660 DOI: 10.1007/s12020-022-03100-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zheng BH, Zhang C, Wan WZ, Sun WT, Cheng X, Ni XJ, Ni XL, Suo T, Liu H, Shen S, Liu HB. The clinical and prognostic factors for biliary neuroendocrine neoplasm: a study based on the SEER database. BMC Surg 2022;22:253. [PMID: 35768809 DOI: 10.1186/s12893-022-01689-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zhang Z, Wang F, Li Z, Ye Z, Zhuo Q, Xu W, Liu W, Liu M, Fan G, Qin Y, Zhang Y, Chen X, Yu X, Xu X, Ji S. Value of lymphadenectomy in patients with surgically resected pancreatic neuroendocrine tumors. BMC Surg 2022;22:160. [PMID: 35538535 DOI: 10.1186/s12893-022-01595-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]